Norstella Executive and Leadership Team

Michael Gallup, the Chief Executive Officer at Norstella, directs the overarching strategy and vision for the organization. Gallup guides Norstella's mission to improve patient access by integrating its market-leading companies, including Citeline, Evaluate, MMIT, Panalgo, and The Dedham Group. This leadership role involves ensuring these entities deliver essential insights for critical strategic and commercial decisions within the life sciences sector. Gallup oversees the company's efforts to provide comprehensive solutions that assist clients throughout the entire drug development life cycle, from pipeline identification to patient delivery. Under Gallup's direction, Norstella leverages scarce data assets and advanced technologies like real-world data, machine learning, and predictive analytics to navigate industry complexities. Michael Gallup's executive oversight ensures the synergistic combination of expertise, data solutions, and advisory services offered by Norstella's constituent organizations, solidifying its position as a premier global pharma intelligence solutions provider.

Michael Doherty, the Chief of Staff To the Chief Executive Officer at Norstella, provides strategic support and operational coordination to Michael Gallup. Doherty facilitates the execution of Norstella's vision, ensuring alignment across departments and initiatives aimed at improving patient access. This role involves managing key projects, streamlining communication channels, and enhancing operational efficiency throughout the organization. The Chief of Staff plays a pivotal part in integrating the efforts of Norstella's constituent companies, including Citeline, Evaluate, MMIT, Panalgo, and The Dedham Group, to maximize their collective impact. Doherty supports the strategic direction of advanced technologies such as real-world data, machine learning, and predictive analytics, ensuring they effectively serve life sciences clients. Michael Doherty's operational expertise is essential for navigating the complexities of the drug development life cycle and reinforcing Norstella's commitment to delivering critical answers for strategic and commercial decision-making.

Daniel Tempesta, the Chief Financial Officer at Norstella, manages the financial health and strategic fiscal planning for the organization. Tempesta oversees all financial operations, including budgeting, forecasting, and resource allocation, ensuring alignment with Norstella's growth objectives and mission to improve patient access. This executive role involves managing the financial integration of Norstella's market-leading companies, such as Citeline, Evaluate, MMIT, Panalgo, and The Dedham Group, to optimize financial performance and investment strategies. The Chief Financial Officer plays a critical part in evaluating new business opportunities and ensuring the financial viability of advanced technology initiatives, including real-world data, machine learning, and predictive analytics. Tempesta's financial leadership supports Norstella's ability to provide essential answers for critical strategic and commercial decision-making within the life sciences sector. Daniel Tempesta's fiscal oversight is instrumental in navigating the complexities of the drug development life cycle and maintaining Norstella's position as a premier global pharma intelligence solutions provider.

Andrew Augustine, the Chief Technology Officer at Norstella, architects the technological infrastructure and innovation strategy. Augustine drives the integration of advanced technologies across Norstella's diverse portfolio, ensuring seamless data flow and robust analytical capabilities. This involves overseeing the development and deployment of cutting-edge solutions, including real-world data platforms, machine learning algorithms, and predictive analytics tools. Augustine's responsibilities extend to enhancing the technological synergy between Norstella's constituent companies, such as Citeline, Evaluate, MMIT, Panalgo, and The Dedham Group, to optimize their data assets and service offerings. The Chief Technology Officer ensures that Norstella's technology stack supports the company's core mission of improving patient access by enabling life sciences clients to make critical strategic and commercial decisions. Augustine's focus remains on leveraging technology to navigate the complexities of the drug development life cycle, from pipeline to patient, and maintaining Norstella's competitive edge in the global pharma intelligence market.

Kevin D'Ambrosia, the Chief Revenue Officer, Heorand Rwe & Rwd & Skipta at Norstella, drives revenue generation and commercial strategy for key business units. D'Ambrosia focuses on maximizing commercial outcomes within the Health Economics and Outcomes Research (HEOR), Real-World Evidence (RWE), and Real-World Data (RWD) domains, alongside the Skipta platform. This leadership position involves developing and executing sales strategies that align with Norstella's mission to improve patient access and support critical decision-making for life sciences clients. D'Ambrosia oversees the commercial teams responsible for delivering advanced data solutions and expert advisory services, ensuring revenue growth and market penetration. The Chief Revenue Officer works to integrate commercial efforts across Norstella's portfolio, enhancing the value proposition for clients navigating the drug development life cycle. Kevin D'Ambrosia's commercial acumen is vital for expanding Norstella's market reach and solidifying its role as a leading pharma intelligence solutions provider.

Joel Keefe, the Chief Revenue Officer, Mmit, Skipta, Panalgo, Rwd & Evidence Generation at Norstella, spearheads revenue growth and commercial strategy for critical business segments. Keefe directs the commercial efforts for MMIT, Skipta, Panalgo, and the Real-World Data (RWD) & Evidence Generation units, focusing on delivering market-leading solutions. This executive role involves cultivating strategic partnerships and expanding market share by ensuring clients receive essential answers for their commercial decision-making needs. Keefe's leadership ensures the effective integration of these specialized units within Norstella's broader mission to improve patient access. The Chief Revenue Officer oversees the sales and business development teams, driving revenue through advanced data solutions and expert advisory services. Joel Keefe's commercial expertise is crucial for navigating the complexities of the drug development life cycle and reinforcing Norstella's position as a global leader in pharma intelligence.